Home > News > Making Sense of the Advances in the Treatment of Hepatocellular Carcinoma
Gastrointestinal Oncology, Liver Cancer
Read Time: 3 mins

Making Sense of the Advances in the Treatment of Hepatocellular Carcinoma

Published Online: November 23rd 2015 Oncology & Hematology Review, 2015;11(2):141–2 DOI: https://doi.org/10.17925/OHR.2015.11.02.141
Authors: Imane El-Dika, Ghassan K Abou-Alfa
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Recent advances in the understanding and management of hepatocellular carcinoma are promising and may usher in a new era in cancer therapy. Here we discuss the latest improvement in hepatitis C antiviral therapy, loco-regional tumor control, c-met inhibitors, and immune therapy. Genetic testing in hepatocellular carcinoma could be a turning point in the treatment development of this fatal disease.

Keywords

Hepatocellular carcinoma, hepatitis C virus, NS3/4A protease inhibitors, trans-arterial chemoembolization, sorafenib, tivantinib, cabozantinib, tremelimumab, nivolumab

Article:

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death, with a rising global incidence.1 The majority of HCC occurs in the setting of liver cirrhosis, mainly due to hepatitis C virus (HCV) infection, hepatitis B viral infection, alcohol consumption, or nonalcoholic fatty liver disease.

The most important development in HCC is the advent of novel curative therapies for HCV. Treatment for HCV infection early in the disease process includes a more than 70 % reduction in the risk for HCC.2 Earlier therapy consisted of the poorly tolerated injectable interferon (IFN), with low efficacy and a high toxicity profile. Recent advances in the treatment of chronic hepatitis C have been achieved through the development of direct-acting antiviral agents that target the nonstructural protein NS3/4A serine protease, which processes the nascent viral poly-protein, allowing for HCV replication.3 Next-generation HCV NS3/4A protease inhibitors inhibit the NS5A replication scaffold, also known as the membranous web, and the NS5B ribonucleic acid (RNA)-dependent RNA polymerase. Among several clinical trials, more than 90 % of patients achieved sustained viral response (SVR) with sofosbuvir,4,5 simeprevir,6 or ledipasvir.7 High efficacy was shown among all subgroups, except for genotypes 1 and 4. While still unclear, the curative effect of these new therapies will probably affect the incidence of HCC.

Management of HCC remains a multidisciplinary approach, especially in the presence of curative treatments in early stage. Screening, risk stratification, and management of liver decompensation are crucial in patient care. Surgery, liver transplant, and radiofrequency ablation remain the standard of care for the curative treatment of early-stage HCC.8

Transarterial chemoembolization (TACE) is the most widely used modality for nonresectable tumors.9 Recently, transarterial embolization (TAE) has shown similar outcome and safety profiles,10 questioning the role of adding doxorubicin. Radioembolization with Y90 is challenging the current paradigm of HCC treatment, despite the lack of any randomized clinical trial data to date.11 Enhancing the treatment effect of antiangiogenic therapy by preventing the angiogenic flare of sorafenib has failed so far.12,13

The advent of sorafenib as a standard of care with an improvement in survival to 10.7 months compared with 7.9 months for placebo (0.69; 95 % confidence interval [CI] 0.55–0.87; p=0.001) opened the door into ample opportunities for the evaluation of other therapeutic options.14 A randomized phase II study of sorafenib plus doxorubicin in firstline treatment of HCC showed improvement in overall survival (OS) of 13.7 months compared with 6.5 months for doxorubicin plus placebo (p=0.0049).15 A large randomized phase III trial followed that.16 However, the study was halted in view of an interim analysis that showed that “it is very unlikely that significant differences in overall survival and progression-free survival will be shown between the treatment arms”,5 based on CALGB 80802 communication.

With overexpression of c-met and its ligand hepatocyte growth factor (HGF) occurring in up to 80 % of HCC, the study of c-met inhibitors is of interest. Tivantinib, a c-met multityrosine kinase inhibitor, was evaluated in patients with advanced HCC in the second-line setting, with doubling of median OS to 7.2 months compared with 3.8 months for placebo, among high c-met expressing tumors.17 Similarly, another c-met multityrosine kinase inhibitor, cabozantinib,18 showed a preliminary improvement in survival up to 15 months in the second-line setting.19 Both drugs are under evaluation in randomized phase III clinical trials against placebo in the second-line setting (www.clinicalTrials. gov identifier: NCT01755767 and NCT01908426).20

Immune escapes have been identifıed to carry a poor outcome with a high likelihood of metastatic spread of HCC and present a novel therapeutic opportunity. Anti-CTLA4 tremelimumab has demonstrated antitumor activity in patients with heavily pretreated unresectable and metastatic HCV-related HCC, and induced a significant decrease in viral load.21 Similarly, MEDI4736, a human immunoglobulin monoclonal antibody programmed death-ligand 1 (PD-L1) inhibitor,22,23 with a median followup of 6 weeks, tumor shrinkage was detectable in multiple tumor types including HCC. Nivolumab, a fully human immunoglobulin G4 (IgG4) monoclonal antibody programmed death-1 (PD-1) inhibitor, was evaluated in a multiple ascending-dose, phase I/II study in patients with HCC.24 Of 41 patients enrolled, 77 % received prior sorafenib. There were two complete responses (5 %) and seven partial responses (18 %). The OS rate at 6 months is 72 %. This wealth of preliminary data of immunomodulators has already delineated the scope of HCC clinical trials for years to come.

Despite all the efforts, the genetics of HCC remain poorly understood. It is important to acknowledge the genetic heterogeneity and complexity of the disease. Several efforts including a global one led by Memorial Sloan Kettering Cancer Center are attempting to interrogate the genetic profile of patient in clusters based on etiology and ethnicity, hoping to help further delineate potential future therapeutic approaches.

Article Information:
Disclosure

Imane El-Dika, MD, and Ghassan K Abou-Alfa, MD, have no conflicts of interests to declare. No funding was received in the publication of this article.

Correspondence

Ghassan K Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, US. E: abou-alg@mskcc.org

Open Access

This article is published under the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, adaptation, and reproduction provided the original author(s) and source are given appropriate credit.

Received

2015-09-16T00:00:00

References

1. Abou-Alfa GK, Marrero J, Renz J, Lencioni R, Hepatocellular carcinoma tumor board: making sense of the technologies, Am Soc Clin Oncol Educ Book, 2015;35:e213–20.
2. Khullar V, Firpi FJ, HCV cirrhosis – New perspectives, World J Hepatol 2015;7:1843–55.
3. McQuaid T, Savini C, Seyedkazemi S, Sofosbuvir, a significant paradigm change in HCV treatment, J Clin Transl Hepatol, 2015;3:27–35.
4. Lawitz E, Mangia A, Wyles D, et al., Sofosbuvir for previously untreated chronic hepatitis C infection, N Engl J Med, 2013;368:1878–87.
5. Jacobson IM, Gordon SC, Kowdley KV, et al., Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options, N Engl J Med, 2013;368:1867–77.
6. Lawitz E, Sulkowski MS, Ghalib R, et al., Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study, Lancet, 2014;384:1756–65.
7. Afdhal N, Zeuzem S, Kwo P, et al., Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection, N Engl J Med, 2014;370:1889–98, 8. Mazzaferro V, Lencioni R, Majno P, Early hepatocellular carcinoma on the procrustean bed of ablation, resection, and transplantation, Semin Liver Dis, 2014;34:415–26.
9. Lencioni R, Kudo M, Ye SL, et al., GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis, Int J Clin Pract, 2014;68:609–17.
10. Brown KT, Gonen M, Do KG, et al., A randomized single blind controlled trial of beads versus doxorubicin-eluting beads for arterial embolization of hepatocellular carcinoma (HCC) ), J Clin Oncol, 2013;31(Suppl. 4) abstr. 143.
11. Salem R, Lewandowski RJ, Mulcahy MF, et al., Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes, Gastroenterology, 2010;138:52–64.
12. Lencioni R, Llovet JM, Han G, et al., Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, doubleblind SPACE trial, J Clin Oncol, 2012;30(Suppl. 4) abstr. LBA154.
13. Kudo M, Imanaka K, Chida N, et al., Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma, Eur J Cancer, 2011;47:2117–27.
14. Llovet JM, Ricci S, Mazzaferro V, et al., Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 2008;359:378–90.
15. Abou-Alfa GK, Johnson P, Knox JK, et al., Randomized, doubleblind study of doxorubicin plus sorafenib and doxorubicin plus placebo in patients with advanced hepatocellular carcinoma, JAMA, 2010;304:2154–60.
16. Sorafenib tosylate with or without doxorubicin hydrochloride in treating patients with locally advanced or metastatic liver cancer. Available at: https://clinicaltrials.gov/ct2/show/ NCT01015833 (accessed August 19, 2015).
17. Santoro A, Rimassa L, Borbath I, et al., Tivantinib for secondline treatment of advanced hepatocellular carcinoma: a randomised, placebo controlled phase 2 study, Lancet Oncol, 2013;14:55–63.
18. Qi XS, Guo XZ, Han GH, et al., MET inhibitors for HCC, World J Gastroenterol, 2015;21:5445–53.
19. Verslype C, Cohn AL, Kelley RK, et al., Activity of cabozantinib (XL184) in hepatocellular carcinoma: results from a phase II randomized discontinuation trial (RDT), J Clin Oncol, 2012;30(Suppl; abstr. 4007).
20. Abou-Alfa GK, Cheng AL, Meyer T, et al., Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426), J Clin Oncol, 2014;32(Suppl. 15):TPS4150.
21. Sangro B, Gomez-Martin C, de la Mata M, et al., A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C, J Hepatol, 2013;59:81–8.
22. Segal NH, Antonia SJ, Brahmer JR, et al., Preliminary data from a multiarm expansion study of MEDI4736, an anti-PD-L1 antibody, J Clin Oncol, 2014;32:5s (Suppl; abstr 3002).
23. Ibrahim R, Stewart R, Shalabi A, PD-L1 blockade for cancer treatment: MEDI4736, Semin Oncol, 2015;42:474–83.
24. El-Khoueiry AB, Melero I, Crocenzi TS, et al., Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC), J Clin Oncol, 2015;33(Suppl.; abstr LBA101).

Further Resources

Share this Article
Related Content In Liver Cancer
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72